Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

to Present at the Cantor Fitzgerald Global Healthcare Conference

LAKE CITY, September 19, 2023 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System

(CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at

the 2023 Cantor Fitzgerald Global Heathcare Conference to take place September 26th to September 28th in New York City.

request a 1x1 meeting with Lipocine management, please contact your representative at Cantor Fitzgerald.

is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery

to develop differentiated products for CNS disorders. Lipocine has drug candidates in development as well as drug candidates for which

we are exploring partnering. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable

benefit to risk profile which target large addressable markets with significant unmet medical needs.

clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101

for the potential treatment of epilepsy and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for

the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate

for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated

cirrhosis, LPCN 1144, our candidate for treatment of non-cirrhotic NASH, and LPCN 1111, a once-a-day therapy candidate for testosterone

replacement therapy (TRT). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is

approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males.

For more information, please visit www.lipocine.com.

release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, the application

of our proprietary platform in developing new treatments for CNS disorders, our product candidates and related clinical trials, our development

of and filing of a NDA with the FDA for any of our product candidates, and the potential uses and benefits of our product candidates.

Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the

risks that we may not be successful in developing product candidates to treat CNS disorders, we may not have sufficient capital to complete

the development processes for our product candidates, we may not be able to enter into partnerships or other strategic relationships

to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits

not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements,

risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval

pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing

and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without

limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov.

Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required

further information: